News
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...
Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...
Eli Lilly (NYSE:LLY) recently saw its stock price rise by 6.63% over the last month, a movement potentially influenced by ...
Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...
The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...
A clinical-stage biotech company based in Redwood City, California, developing tissue-restorative biologics for chronic ...
California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and multi-target research ...
Juvena Therapeutics & Eli Lilly and Company ink research collaboration focused on muscle health: Redwood City, California Saturday, June 14, 2025, 15:00 Hrs [IST] Juvena Therapeut ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins ...
Biotechnology startup Juvena Therapeutics Inc. has raised $41 million in new venture-capital funding to advance technology that could expand the range of treatments for chronic conditions and ...
REDWOOD CITY, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle ...
Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by Juvena Collaboration aims to accelerate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results